Literature DB >> 19546553

Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation.

Andreas H Mahnken1, Philipp Bruners, Rolf W Günther.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. Surgery and transarterial chemoembolization have for many years dominated the local treatment of HCC. The introduction of image-guided percutaneous techniques for local tumor ablation changed the treatment of liver cancer. Percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) have both successfully been employed in the treatment of HCC. In current guidelines both techniques are recommended as standard therapy in limited liver cancer. From the current literature both techniques have to be considered safe and effective in the treatment of HCC. Several randomized trials showed RFA to be superior to PEI for treating small HCC. Moreover, several studies analyzed survival after PEI or RFA in comparison with surgery, proving interventional therapy to be a serious competitor of resection. With introduction of combined interventional therapies including transarterial chemoembolization, PEI and RFA survival was improved further. In this article, we provide an insight into the technical basics of PEI and RFA and review the clinical results and indications of these interventional techniques in the treatment of HCC. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546553     DOI: 10.1159/000218347

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  14 in total

1.  Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation?

Authors:  Jung Hyeok Kwon
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

2.  Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma.

Authors:  Shuhuai Wang; Xinmei Kang; Shouqiang Cao; Hui Cheng; Di Wang; Jingshu Geng
Journal:  Dig Dis Sci       Date:  2012-06-22       Impact factor: 3.199

Review 3.  Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation.

Authors:  Meera Ramanathan; Michael Shroads; Myunghan Choi; David Wood; Anil Seetharam
Journal:  J Gastrointest Oncol       Date:  2017-10

4.  Multifunctional Liposomes for Image-Guided Intratumoral Chemo-Phototherapy.

Authors:  Dyego Miranda; Kevin Carter; Dandan Luo; Shuai Shao; Jumin Geng; Changning Li; Upendra Chitgupi; Steven G Turowski; Nasi Li; G Ekin Atilla-Gokcumen; Joseph A Spernyak; Jonathan F Lovell
Journal:  Adv Healthc Mater       Date:  2017-05-15       Impact factor: 9.933

5.  Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Ming-De Lu; Xiao-Yan Xie; Zuo-Feng Xu; Guang-Jian Liu; Lin-Na Liu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 6.  Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Authors:  William Jarnagin; William C Chapman; Steven Curley; Michael D'Angelica; Charles Rosen; Elijah Dixon; David Nagorney
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

7.  Alcoholization of pyogenichepatic abscess with absolute alcohol in Bama minipigs.

Authors:  Ru-Gang Zhang; Xiu-Li Zhang; Yun-Sheng Yang
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

8.  Advantages of Laparoscopic Radiofrequency Ablation Over Percutaneous Radiofrequency Ablation in Hepatocellular Carcinoma.

Authors:  Hyuk Soo Eun; Byung Seok Lee; In Sun Kwon; Gee Young Yun; Eaum Seok Lee; Jong Seok Joo; Jae Kyu Sung; Hee Seok Moon; Sun Hyung Kang; Ju Seok Kim; Hae Jin Shin; Tae Kyun Kim; Kwangsik Chun; Seok Hyun Kim
Journal:  Dig Dis Sci       Date:  2017-07-25       Impact factor: 3.199

9.  Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy.

Authors:  Sung Hoon Kim; Sae Byeol Choi; Jae Gil Lee; Seung Up Kim; Mi-Suk Park; Do Young Kim; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2011-02-19       Impact factor: 3.452

10.  131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment.

Authors:  Yu Ma; Ligeng Duan; Lin Li; Wusheng Lu; Bo Li; Xiaoli Chen
Journal:  J Gastrointest Oncol       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.